BioCryst Pharmaceuticals | BCRX - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
BioCryst Pharmaceuticals USD 84.08M 3.95M 2025-09
Chugai Pharma JPY 456.43B 40.66B 2025-09
Daiichi Sankyo JPY 542.16B 97.68B 2025-09
DBV Technologies USD 69.84M 33.37M 2025-09
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Gilead Sciences USD 7.33B 2.19B 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
Glaxosmithkline GBP 3.3B 303M 2025-09
Incyte USD 3.58B 650.78M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
Karyopharm Therapeutics USD 37.67M 1.05M 2025-09
Neurocrine Biosciences USD 713M 372.8M 2025-12
Novavax USD 268.02M 14.28M 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12